FK866 (APO866): NAMPT Inhibitor Benchmarks in Hematologic Cancer Research

Executive Summary: FK866 (APO866), a highly specific non-competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), achieves sub-nanomolar inhibition (Ki = 0.4 nM) in vitro, resulting in profound NAD and ATP depletion in hematologic cancer cells, especially acute myeloid leukemia (AML) lines, while sparing normal human hematopoietic progenitors (APExBIO, product page). The compound elicits caspase-independent cell death, characterized by mitochondrial membrane depolarization and autophagy induction (Hasmann 2003, DOI). FK866 demonstrates significant in vivo antitumor efficacy, including tumor growth suppression and survival extension in murine xenograft models (Liu 2020, DOI). FK866 is insoluble in water but readily soluble in DMSO and ethanol, supporting a range of in vitro and in vivo workflows (APExBIO, A4381 datasheet). All claims herein are supported by peer-reviewed studies and stable product documentation.

Biological Rationale

Nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the rate-limiting step in the salvage pathway of nicotinamide adenine dinucleotide (NAD) biosynthesis. NAD is critical for cellular metabolism, DNA repair, and cell survival (Ji et al., 2025). Cancer cells, particularly hematologic malignancies like AML, exhibit elevated NAD turnover, rendering them selectively vulnerable to NAMPT inhibition. Targeting NAMPT disrupts NAD-dependent enzymatic functions, impairs energy metabolism, and induces cell death (internal review). FK866 (APO866) leverages this synthetic lethality, maximizing selectivity for transformed cells while minimizing toxicity in normal tissues.

Mechanism of Action of FK866 (APO866)

FK866 (APO866) is a non-competitive NAMPT inhibitor, meaning it binds at an allosteric site rather than at the substrate-binding pocket (APExBIO). The inhibition constant (Ki) is 0.4 nM, and reported IC50 values range from 0.09 nM to 27.2 nM, depending on the cell context and assay system. By blocking NAMPT, FK866 halts the conversion of nicotinamide to nicotinamide mononucleotide (NMN), depleting the intracellular NAD pool. This process leads to rapid ATP depletion, mitochondrial membrane depolarization, and ultimately caspase-independent cell death (Hasmann 2003). Autophagy is also induced, contingent on de novo protein synthesis. Notably, FK866's cytotoxic effects are preferentially observed in AML and other hematologic cancer cells, with reduced toxicity to normal hematopoietic progenitors.

Evidence & Benchmarks

• FK866 inhibits NAMPT with a Ki of 0.4 nM, achieving potent blockade of NAD synthesis in vitro (APExBIO data).
• IC50 values for FK866 range from 0.09 nM (HL-60 AML cells) to 27.2 nM (context-dependent), demonstrating high potency (APExBIO datasheet).
• In AML models, FK866 causes rapid NAD and ATP depletion, selective apoptosis, and cell cycle arrest (Hasmann 2003).
• Cell death occurs via a caspase-independent mechanism involving mitochondrial membrane depolarization and autophagy (Hasmann 2003).
• In mouse xenograft models, FK866 administration prevents tumor growth and prolongs survival in AML and lymphoblastic lymphoma (dosing: 10–30 mg/kg/day, i.p., 2–4 weeks) (Liu 2020).
• Normal human hematopoietic progenitor cells are less sensitive to FK866-induced cytotoxicity, supporting a therapeutic window (Hasmann 2003).
• FK866 solubility profile: insoluble in water, soluble in DMSO (≥19.6 mg/mL) and ethanol (≥49.6 mg/mL), supporting diverse assay platforms (APExBIO).

Applications, Limits & Misconceptions

FK866 (APO866) is primarily used in hematologic cancer research, especially in acute myeloid leukemia (AML) and lymphoblastic lymphoma models. It is also valuable for dissecting cancer metabolism, NAD biosynthesis pathways, and mechanisms of cell death in oncology and vascular aging. For advanced workflows and troubleshooting, see FK866 (APO866): NAMPT Inhibitor Workflows for Hematologic Cancer, which details protocol nuances and extends this article by focusing on reproducibility in complex cancer models. To explore real-world laboratory integration and reproducibility, Harnessing FK866 (APO866): Reliable NAMPT Inhibition provides five scenarios, while the present article updates these with the latest potency and selectivity benchmarks.

Common Pitfalls or Misconceptions

• FK866 is not effective in cancers relying predominantly on the de novo NAD biosynthesis pathway rather than the NAMPT salvage pathway (Hasmann 2003).
• Water-based stock solutions are not recommended due to insolubility; always use DMSO or ethanol for dissolution (product page).
• FK866 does not induce classic caspase-dependent apoptosis; misattribution of cell death mechanisms can confound analysis (Hasmann 2003).
• Cell selectivity is context-dependent; some non-hematologic cell lines may be less responsive due to lower NAD turnover or alternative salvage pathways (Ji et al., 2025).
• Long-term storage of solutions above -20°C or repeated freeze-thaw cycles may degrade FK866 potency (APExBIO, A4381 datasheet).

Workflow Integration & Parameters

FK866 (APO866) is supplied as a solid, with a molecular formula of C₂₄H₂₉N₃O₂. For in vitro assays, dissolve in DMSO (≥19.6 mg/mL) or ethanol (≥49.6 mg/mL) and prepare aliquots for single use. For in vivo studies, dilute to working concentration in appropriate vehicle (commonly 10% DMSO, 90% PBS or saline) immediately before injection. Storage at -20°C is recommended for both solid and stock solutions; avoid repeated freeze-thaw cycles. Use within several months for optimal potency. For experiment design, reference dose-response data and select cell lines with high NAD turnover for maximal effect. For advanced workflows, troubleshooting, and integration into cancer metabolism and vascular aging pipelines, see FK866 (APO866): NAMPT Inhibitor Workflows for Cancer and Senescence Biology; this article clarifies recent selectivity data and product handling updates.

Conclusion & Outlook

FK866 (APO866) from APExBIO (SKU A4381) is a validated, highly potent non-competitive NAMPT inhibitor for hematologic cancer and cancer metabolism research. It enables selective NAD depletion, induces caspase-independent cell death, and demonstrates robust antitumor efficacy in preclinical models. While selectivity and solubility constraints exist, adherence to validated workflows and awareness of mechanistic boundaries maximize reproducibility and impact. Ongoing research continues to expand FK866's utility in oncology and metabolic disease models (Ji et al., 2025).